These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Contragestion with late luteal administration of RU 486 (Mifepristone).
    Author: Dubois C, Ulmann A, Baulieu EE.
    Journal: Fertil Steril; 1988 Oct; 50(4):593-6. PubMed ID: 3049166.
    Abstract:
    The efficacy and tolerance of RU 486 prescribed as a late luteal contragestive agent have been evaluated in 139 women at risk of pregnancy. They were given 400 or 600 mg of RU 486 once on the day before the expected menses. Among these women, 48 (34.5%) were pregnant (positive plasma beta-human chorionic gonadotropin, [beta-hCG]) at the time of RU 486 intake. Bleeding occurred in all but six women. An ongoing pregnancy after treatment was found in nine cases (failure rate, 9/48, 18.8%), which was subsequently terminated by surgical procedure in all cases. There was no disturbance in the menstrual cycle, and the tolerance was very satisfactory. In conclusion, this method is acceptable for women at risk of pregnancy in whom other usual postcoital contraceptive methods cannot be prescribed. 139 women at risk pregnancy (due to unprotected sexual intercourse) participated in a multicenter assessment of the efficacy and tolerability of RU 486 prescribed as a late luteal contragestive agent. 24 women received 400 mg of RU 486 and the remaining 115 women received 600 mg on the day before the expected menses. 48 women (35%) were found to be pregnant (positive plasma beta-human chorionic gonadotropin) at the time of RU 486 intake. An ongoing pregnancy after RU 486 treatment was found in 9 cases (failure rate, 19%). Bleeding occurred in all but 6 women, 1 of whom was pregnant. The duration of bleeding was 4.6 + or - 2.9 days in pregnant women and 3.8 + or - 1.2 days in nonpregnant women. A posttreatment menstrual period occurred 31.8 + or - 6.2 days after the onset of RU 486-induced bleeding in pregnant women and 30.0 + or - 5.3 days afterwards in nonpregnant women. Few side effects were reported (asthenia, pelvic pain, headache, mailase, and dizziness), and none required specific measures. These results indicate that, when it is too late for postcoital contragestive methods and too early for vacuum aspiration abortion, RU 486 constitutes a technique with at least as much effectiveness as high-dose estrogen therapy and fewer side effects and disturbances in the menstrual cycle. However, since the success rate is only 80%, it is essential to schedule a posttreatment visit to identify women with ongoing pregnancies or incomplete uterine evacuation.
    [Abstract] [Full Text] [Related] [New Search]